YSB Pharmacist Co., Ltd. (YSB) has released its mid-term report for 2024, which covers the company's business review and outlook, financial summary, management discussion and analysis, and other content. The report shows that YSB achieved a total GMV of RMB 23.83 billion in the first half of 2024, an 8.1% year-on-year increase. The profit for the period was RMB 13.354 million, compared to a loss of RMB 31.7658 million in the same period last year. The company continues to strengthen policy support and innovation in the outpatient pharmaceutical market, and improve service capabilities through technological empowerment. During the reporting period, YSB's business maintained high-quality growth and engaged in strategic cooperation and business expansion in multiple areas. As of June 30, 2024, the company's cash and cash equivalents amounted to RMB 140.49 million. No significant events were found after the reporting period.

YSB Pharmacist Co., Ltd. (YSB) has released its mid-term report for 2024, which covers the company's business review and outlook, financial summary, management discussion and analysis, and other content. The report shows that YSB achieved a total GMV of RMB 23.83 billion in the first half of 2024, an 8.1% year-on-year increase. The profit for the period was RMB 13.354 million, compared to a loss of RMB 31.7658 million in the same period last year. The company continues to strengthen policy support and innovation in the outpatient pharmaceutical market, and improve service capabilities through technological empowerment. During the reporting period, YSB's business maintained high-quality growth and engaged in strategic cooperation and business expansion in multiple areas. As of June 30, 2024, the company's cash and cash equivalents amounted to RMB 140.49 million. No significant events were found after the reporting period.